01Purpose and principlesWhat the treatment does and how it fits into care.
Calcineurin normally dephosphorylates nuclear-factor signalling proteins that enter the nucleus and promote cytokine transcription. Tacrolimus and pimecrolimus bind intracellular immunophilins and interrupt this pathway, reducing T-cell activation and inflammatory mediator release. Unlike corticosteroids they do not inhibit collagen synthesis enough to cause skin atrophy, which makes them useful on eyelids, face, folds and genital skin when repeated steroid exposure is problematic. They remain local immunomodulators, however, and do not remove infection or malignancy risk.
NICE TA82 links use to a specific decision, not to steroid fear alone. Confirm that the eczema diagnosis is sound, emollient and topical corticosteroid were prescribed in an adequate vehicle and quantity, technique was demonstrated and adherence barriers were addressed. For adults, tacrolimus is an option for moderate-to-severe disease not adequately controlled by topical corticosteroids or when serious adverse-effect risk exists. In children aged 2 and over, the approved strength and disease severity matter. Pimecrolimus is particularly positioned for mild-to-moderate face or neck disease in ages 2–16 when atrophy risk is important.
Counselling determines persistence. Burning often begins soon after application and improves as inflammation settles; cooling the product and applying to dry skin can improve tolerability if consistent with product instructions. Alcohol can provoke flushing in some tacrolimus users. Explain sun avoidance, infection actions and when to stop. There is no routine blood-drug or laboratory monitoring for limited topical use, so repeated face-to-face inspection, quantity review and scrutiny of any persistent focal lesion are the principal safety checks.
Key points
- Tacrolimus and pimecrolimus inhibit calcineurin-dependent T-cell signalling and cytokine release without causing corticosteroid skin atrophy.
- They are not first-line treatment for ordinary atopic eczema: NICE positions them second line when appropriate topical corticosteroid control fails or serious atrophy risk is important.
- Initiation should be by a clinician with a special interest and experience in dermatology after the diagnosis, severity, site and prior corticosteroid technique are confirmed.
- Tacrolimus 0.03% ointment is used from age 2 years; 0.1% is an adult and age-16-and-over strength under its licensed eczema pathway.
- Pimecrolimus 1% cream is a NICE second-line option for mild or moderate facial and neck eczema in children aged 2–16 years when steroid atrophy risk is serious.
- Transient warmth, stinging or burning is common during the first days and usually reduces; severe pain, vesicles or deterioration is not routine adjustment.
- Do not apply to clinically infected skin, beneath occlusion, or directly to mucosa, and use handwashing and a mapped treatment area.
- Minimise natural and artificial ultraviolet exposure, avoid sunbeds and use clothing and broad-spectrum protection; combining treatment with phototherapy needs specialist direction.
- Twice-weekly tacrolimus maintenance on non-consecutive days can prevent flares in selected frequent relapsers who responded to induction, with formal review rather than indefinite automatic repeats.
- Vitiligo, genital or facial psoriasis and several other dermatoses may use calcineurin inhibitors off label; record the evidence, alternatives, consent and outcome separately from licensed eczema use.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Recurrent eczema on eyelid, face, neck or fold with serious corticosteroid-atrophy risk may favour a calcineurin inhibitor after first-line treatment is verified.
Warmth, tingling or stinging begins shortly after application during early treatment, remains local and usually lessens over several days.
New crust, purulence, spreading warmth, painful vesicles or punched-out erosions represents possible bacterial or viral infection rather than ordinary irritation.
Persistent sharply application-limited eczema, swelling or worsening after every dose suggests vehicle irritation or contact allergy and requires product review.
Vitiligo, facial or genital psoriasis and other non-eczema uses require an explicit diagnosis, counselling and defined trial because the eczema licence does not transfer automatically.
Persistent unexplained nodes, constitutional symptoms or nodes that do not resolve after treating infection require examination and specialist assessment before continuation.
A lasting indurated, ulcerated, bleeding or otherwise atypical lesion should be biopsied or referred rather than suppressed repeatedly with local immunomodulation.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Diagnosis and severity confirmationFirst step - Why
- Ensure a supported inflammatory diagnosis and treatment threshold before initiation.
- Interpretation and limitations
- Map morphology, site, extent and life impact and reconsider tinea, contact dermatitis, rosacea, periorificial dermatitis and malignancy when the pattern is atypical.
- 02
Observed topical-treatment auditFirst line - Why
- Show that appropriate first-line corticosteroid and emollient care genuinely failed or carried serious risk.
- Interpretation and limitations
- Review actual tubes, potency, quantities, sites, duration and application; inadequate supply or fear-driven underuse is corrected before declaring treatment failure.
- 03
Age, site and strength check - Why
- Prevent selection of the wrong tacrolimus strength or unsupported pimecrolimus pathway.
- Interpretation and limitations
- Confirm age at initiation, disease severity and site against NICE guidance and the current SmPC; document when use is off label.
- 04
Bacterial swab or HSV PCR - Why
- Diagnose infection when pustules, crust, vesicles, pain or rapid worsening appears.
- Interpretation and limitations
- Sample a fresh representative lesion, but suspected eczema herpeticum or invasive infection requires treatment without waiting for the result.
- 05
Lymph-node assessment - Why
- Separate reactive nodes from persistent unexplained lymphadenopathy.
- Interpretation and limitations
- Examine drainage sites and infection, document size and duration and refer persistent, enlarging or systemic-symptom-associated nodes rather than simply stopping and ignoring them.
- 06
Biopsy or patch testing - Why
- Resolve a persistent focal lesion, unusual morphology or suspected allergy.
- Interpretation and limitations
- Biopsy representative induration or ulcer and use patch testing for relevant vehicle or product allergy; neither routine test is required for typical responsive eczema.
04Treatment approachPreparation, options, escalation and aftercare.
01First-line eligibilityVerify the second-line indicationFirst stepFirst lineSecond lineA topical calcineurin inhibitor is being considered for atopic eczema.+
- 1Confirm diagnosis, severity and sensitive-site burden and review a correctly delivered topical corticosteroid and emollient plan.
- 2Establish inadequate control or a serious corticosteroid adverse-effect risk and have an experienced clinician select tacrolimus or pimecrolimus by age, site and severity.
- 3Discuss licence, expected burning, infection actions, ultraviolet avoidance, amount, duration and alternatives and record any off-label element.
02Tacrolimus inductionUse the age-appropriate strengthTacrolimus is selected for a licensed atopic-eczema course.+
- 1For ages 2–15 use tacrolimus 0.03% ointment twice daily for up to three weeks, then once daily until lesions clear, following the current product plan.
- 2For age 16 and over, use 0.1% ointment twice daily to affected skin until clear, then consider reduced strength or maintenance according to response and product guidance.
- 3Review if no improvement by two weeks, if prolonged continuous treatment is needed or if burning, infection or a new focal lesion makes the diagnosis uncertain.
03Proactive maintenancePrevent frequent flares on two daysA patient with frequent eczema flares responded to tacrolimus induction and maintenance is appropriate.+
- 1Apply the age-appropriate strength once daily on two non-consecutive days each week to sites that usually flare, leaving two or three treatment-free days between applications.
- 2Treat an established flare by returning to the induction schedule after checking infection, and continue daily emollient care.
- 3Review maintenance response and safety within 12 months and stop or revise a plan that no longer reduces flare burden.
04Infection responsePause local immunomodulation and treat the organismCrust, purulence, vesicles, punched-out erosions, fever or rapid spread develops.+
- 1Stop the calcineurin inhibitor on infected skin and assess same day for eczema herpeticum, cellulitis, impetigo or varicella.
- 2Obtain culture or PCR where useful and start systemic antiviral or antibacterial treatment immediately when clinical severity requires it.
- 3Restart only after infection is controlled, the skin is re-examined and a clinician confirms that continued treatment remains appropriate.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Tacrolimus 0.03% ointment
For ages 2–15 years with licensed atopic eczema, apply thinly twice daily for up to 3 weeks then once daily until clear; adults may use this strength when stepping down. Selected maintenance uses once daily on 2 non-consecutive days each week.Do not use under age 2, on clinically infected skin or beneath occlusion. Explain early burning, UV avoidance, alcohol flushing, lymph-node review and product-specific vaccination advice.
Tacrolimus 0.1% ointment
For people aged 16 years and over, apply thinly twice daily to affected atopic-eczema skin until clear; use the product-guided step-down or twice-weekly non-consecutive maintenance schedule after response.Avoid infection, mucosa, occlusion, sunbeds and unnecessary UV exposure. Reassess failure at 2 weeks, unexplained nodes and any persistent indurated or ulcerated focus.
Pimecrolimus 1% cream
Apply a thin layer twice daily to affected skin under the licensed product and NICE pathway, continuing only while active and stopping when clear; review if improvement is absent after several weeks.Specialist-experienced initiation is required under TA82. Do not apply to infected skin or under occlusion; counsel about burning, UV exposure, off-label sites and product licensing by age.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Review response by two weeks for tacrolimus induction and revisit diagnosis, infection, technique and contact allergy if control is not emerging.
- Ask about burning duration, flushing, sun or sunbed exposure, new crust or vesicles and any unscheduled occlusive use.
- Check the actual strength, tube quantity, treated sites and age because 0.03% and 0.1% tacrolimus are not interchangeable labels.
- Inspect persistent focal lesions and lymph nodes and refer or biopsy when morphology or duration is not explained by eczema.
- For twice-weekly maintenance, document flare frequency and corticosteroid rescue before and after treatment and review at least annually.
- No routine blood concentration or laboratory panel is needed for ordinary limited topical use; test only a clinically defined problem.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Atrophy sparing is not risk free
Calcineurin inhibitors preserve dermal collagen better than corticosteroids but still require infection, ultraviolet and focal-lesion vigilance.
Burning follows barrier failure
Application sting is often strongest on acutely inflamed skin and declines as barrier and inflammation improve, unlike spreading viral pain.
Strength follows age
Tacrolimus 0.1% is not simply the next step for a young child whose 0.03% course failed; diagnosis and specialist strategy come first.
Maintenance is intermittent
The licensed proactive concept uses two non-consecutive days rather than continuous twice-daily application to normal skin indefinitely.
UV advice is active treatment
Avoiding tanning beds and excessive sunlight and using clothing and sunscreen are necessary because intentional ultraviolet combination is specialist territory.
Off-label is diagnosis specific
Evidence supporting facial vitiligo cannot be assumed to establish efficacy for every genital, pigmentary or inflammatory eruption.
08Common pitfallsFrequent interpretation and management errors.
- 01
Using a topical calcineurin inhibitor as first treatment without checking an adequate corticosteroid and emollient plan.
- 02
Prescribing tacrolimus 0.1% to a child under 16 because the lower strength did not work immediately.
- 03
Calling painful vesicles expected burning and missing eczema herpeticum.
- 04
Combining routine phototherapy or sunbed exposure with tacrolimus without specialist governance.
- 05
Continuing on a persistent ulcerated or indurated lesion instead of arranging diagnosis.
- 06
Applying beneath wraps or to mucosa because the medicine does not cause steroid atrophy.
- 07
Presenting an off-label vitiligo or psoriasis regimen as though it were licensed atopic-eczema use.
- 08
Renewing twice-weekly maintenance without reviewing whether it reduced flares.